The abstract is read at the publisher; the summary is JClub's.
Higher serum 6:2 FTEO6, 6:2 FTEO8, and 6:2 FTEO9 levels are associated with increased intracranial aneurysm risk in a case-control study, with odds ratios up to 2.78.
- Why it matters: Whether exposure to 6:2 fluorotelomer ethoxylates is linked to intracranial aneurysm risk is unknown, despite rising detection in environmental media and human serum.
- What they did: In a case-control design (137 IA patients, 274 healthy controls), the team quantified seven serum 6:2 FTEO homologues and ran nontargeted metabolomic profiling, then used adjusted quartile comparisons, weighted quantile sum, and random forest.
- The result: Adjusted odds ratios for highest versus lowest quartiles were 2.68 (95% CI 1.61–3.70) for 6:2 FTEO6, 2.78 (1.78–3.81) for 6:2 FTEO8, and 1.98 (1.10–3.58) for 6:2 FTEO9; combined exposure was significant and random forest highlighted lipid pathways, with exploratory mediation compatible with arachidonic acid metabolism and phosphatidylcholine biosynthesis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.